The Effects of Oral Calcitonin on Bone Collagen Maturation: Implications for Bone Turnover and Quality

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2008 Apr 4

PMID 18385918

Citations 10

Authors

M A Karsdal

I Byrjalsen

D J Leeming

P D Delmas

C Christiansen

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Anti-resorptive strategies may affect bone collagen maturation differently depending on the mode of action. Orally administrated calcitonin resulted in a dose dependent inhibition of bone resorption but did not change bone collagen maturation. This may reflect aspects of bone quality.

Introduction: The aim of the present study was to evaluate the effect of oral calcitonin on bone collagen maturation measured as the ratio between the degradation products of newly synthesized C-telopeptides of type I collagen (alphaalphaCTX) and mature isomerized betabetaCTX in postmenopausal women.

Methods: Participants were from a phase II study. A total of 168 postmenopausal women were included and treated with placebo, 0.15, 0.4, 1, or 2.5 mg calcitonin daily. The non-isomerized alphaalphaCTX and isomerized betabetaCTX were measured in 24-hour urine samples obtained at baseline, and after 1 day, 1 month and 3 months of therapy.

Results: Calcitonin, significantly and dose-dependently inhibited bone resorption by up to 50% as measured by alphaalphaCTX and isomerized betabetaCTX. Bone collagen maturation measured as the ratio between alphaalphaCTX and betabetaCTX remained unchanged during treatment with calcitonin.

Conclusions: Calcitonin dose-dependently and significantly reduced both alphaalphaCTX to betabetaCTX levels in urine without affecting the alphaalphaCTX to betabetaCTX ratio. This is in direct contrast to other anti-resorptive therapies, in which strong treatment-dependent effect on the endogenous age profile of bone has been observed. These data highlight that even though the treatments may have comparable effects on BMD, endogenous bone composition, which may be associated to bone quality, is strongly affected by the type of intervention, in which calcitonin display highly divergent effects from that of other anti-resorptives.

Citing Articles

Clinical monitoring in osteoarthritis: Biomarkers.

Kraus V, Karsdal M Osteoarthritis Cartilage. 2021; 30(9):1159-1173.

PMID: 34536529 PMC: 8924021. DOI: 10.1016/j.joca.2021.04.019.

New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation.

Aguilar M, Rose R, Takawale A, Nattel S, Reilly S Cardiovasc Res. 2021; 117(7):1645-1661.

PMID: 33723575 PMC: 8208746. DOI: 10.1093/cvr/cvab080.

Lessons learned from the clinical development of oral peptides.

Karsdal M, Riis B, Mehta N, Stern W, Arbit E, Christiansen C Br J Clin Pharmacol. 2014; 79(5):720-32.

PMID: 25408230 PMC: 4415709. DOI: 10.1111/bcp.12557.

Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis.

Huebner J, Bay-Jensen A, Huffman K, He Y, Leeming D, McDaniel G Arthritis Rheumatol. 2014; 66(9):2440-9.

PMID: 24909851 PMC: 4152234. DOI: 10.1002/art.38739.

Oral calcitonin.

Hamdy R, Daley D Int J Womens Health. 2012; 4:471-9.

PMID: 23071417 PMC: 3469233. DOI: 10.2147/IJWH.S24776.

References

Rogers M . New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9(32):2643-58. DOI: 10.2174/1381612033453640. View

Schuit S, van der Klift M, Weel A, de Laet C, Burger H, Seeman E . Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34(1):195-202. DOI: 10.1016/j.bone.2003.10.001. View

Greenspan S, Parker R, Ferguson L, Rosen H, Karpf D . Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998; 13(9):1431-8. DOI: 10.1359/jbmr.1998.13.9.1431. View

Karsdal M, Martin T, Bollerslev J, Christiansen C, Henriksen K . Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res. 2007; 22(4):487-94. DOI: 10.1359/jbmr.070109. View

Cloos P, Fledelius C . Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential. Biochem J. 2000; 345 Pt 3:473-80. PMC: 1220780. View

Ravn P, Hosking D, Thompson D, Cizza G, Wasnich R, McClung M . Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999; 84(7):2363-8. DOI: 10.1210/jcem.84.7.5847. View

Chambers T, Moore A . The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab. 1983; 57(4):819-24. DOI: 10.1210/jcem-57-4-819. View

Faulkner K . Bone matters: are density increases necessary to reduce fracture risk?. J Bone Miner Res. 2000; 15(2):183-7. DOI: 10.1359/jbmr.2000.15.2.183. View

Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard B, Sumer E, Tanko L . In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol. 2005; 3(5):553-80. DOI: 10.1089/adt.2005.3.553. View

10.

Stepan J, Burr D, Pavo I, Sipos A, Michalska D, Li J . Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone. 2007; 41(3):378-85. DOI: 10.1016/j.bone.2007.04.198. View

11.

Viguet-Carrin S, Roux J, Arlot M, Merabet Z, Leeming D, Byrjalsen I . Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006; 39(5):1073-1079. DOI: 10.1016/j.bone.2006.05.013. View

12.

Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas P . Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res. 2002; 17(5):826-33. DOI: 10.1359/jbmr.2002.17.5.826. View

13.

Ravn P, Clemmesen B, Christiansen C . Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999; 24(3):237-44. DOI: 10.1016/s8756-3282(98)00183-5. View

14.

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

15.

Siris E, Miller P, Barrett-Connor E, Faulkner K, Wehren L, Abbott T . Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286(22):2815-22. DOI: 10.1001/jama.286.22.2815. View

16.

Hui S, Slemenda C, JOHNSTON Jr C . Age and bone mass as predictors of fracture in a prospective study. J Clin Invest. 1988; 81(6):1804-9. PMC: 442628. DOI: 10.1172/JCI113523. View

17.

Takahashi H, EPKER B, Frost H . RESORPTION PRECEDES FORMATIVE ACTIVITY. Surg Forum. 1964; 15:437-8. View

18.

Miller P, Siris E, Barrett-Connor E, Faulkner K, Wehren L, Abbott T . Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res. 2002; 17(12):2222-30. DOI: 10.1359/jbmr.2002.17.12.2222. View

19.

Grados F, Brazier M, Kamel S, Mathieu M, Hurtebize N, Maamer M . Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab. 2003; 88(11):5175-9. DOI: 10.1210/jc.2002-021968. View

20.

Mori S, Harruff R, Ambrosius W, Burr D . Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone. 1998; 21(6):521-6. DOI: 10.1016/s8756-3282(97)00200-7. View